CD274 and bladder transitional cell carcinoma: A 2016 study reported that a PD-L1 monoclonal antibody, durvalumab (MEDI4736), exhibited some clinical efficacy in patients with bladder urothelial carcinoma receiving multiline therapy (Massard et al., 2016).